MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress.
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Mayo Clinic in Arizona, Universitair Ziekenhuis Leuven, KU Leuven, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, University of Milan, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, National Cancer Center Hospital East, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Ludwig-Maximilians-Universität München, Merck & Co., Inc., Rahway, NJ, USA (United States), Seagen (United States), Inserm, Sorbonne Université, Hôpital Saint-Antoine, Centre de Recherche Saint-Antoine, Duke Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Seagen
OpenAlex ID: W4317891399